NCT04455451已完成不适用
Intensive Care Therapy of Covid-19 Disease in Germany an Multi-center Observational Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,054
- 试验地点
- 27
- 主要终点
- Mortality
研究概览
简要总结
Multi-center retrospective and prospective observational study of Covid-19 patients with severe or critical illness treated on a German ICU
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age above 18 years
- •Covid-19 disease (positive SARS-CoV-2 PCR)
排除标准
- 未提供
结局指标
主要结局
Mortality
时间窗: up to 150 days
ICU Mortality of patients
次要结局
- ICU length of stay(up to 150 days)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
不适用
Outcomes of Patients With COVID-19 in the Intensive Care UnitCoronavirus InfectionsCOVID-19Viral Pneumonia Human CoronavirusNCT04336345Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran150
招募中
不适用
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.Indolent B-Cell Non-Hodgkin LymphomaCOVID-19Chronic Lymphocytic LeukemiaNCT05803395Gruppo Italiano Malattie EMatologiche dell'Adulto954
撤回
不适用
FOLLOW-UP OF PATIENTS WITH COVID-19.Patient Admitted to Intensive Care Unit for COVID-19NCT04609839University Hospital, Strasbourg, France200
Unknown
不适用
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in ShanghaiCOVID-19NCT05422963Ruijin Hospital1,000
已完成
不适用
Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab ApplicationCOVID-19Outcome, FatalTocilizumabInterleukin 6Critically IllNCT06233357University of Ulm95